Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

240 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mucosal bacille calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses.
Hoft DF, Brown RM, Belshe RB. Hoft DF, et al. Among authors: belshe rb. Clin Infect Dis. 2000 Jun;30 Suppl 3:S217-22. doi: 10.1086/313864. Clin Infect Dis. 2000. PMID: 10875787 Clinical Trial.
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.
Winokur PL, Patel SM, Brady R, Chen WH, El-Kamary SS, Edwards K, Creech CB, Frey S, Keitel WA, Belshe R, Walter E, Bellamy A, Hill H. Winokur PL, et al. Among authors: belshe r. J Infect Dis. 2015 Aug 15;212(4):525-30. doi: 10.1093/infdis/jiv087. Epub 2015 Feb 23. J Infect Dis. 2015. PMID: 25712967 Free PMC article. Clinical Trial.
Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.
Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Bernstein DI, et al. Among authors: belshe r. J Infect Dis. 2008 Mar 1;197(5):667-75. doi: 10.1086/527489. J Infect Dis. 2008. PMID: 18260764 Clinical Trial.
Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children.
Belshe RB, Gruber WC. Belshe RB, et al. Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1947-51. doi: 10.1098/rstb.2001.0982. Philos Trans R Soc Lond B Biol Sci. 2001. PMID: 11779396 Free PMC article. Clinical Trial.
Prevention of otitis media in children with live attenuated influenza vaccine given intranasally.
Belshe RB, Gruber WC. Belshe RB, et al. Pediatr Infect Dis J. 2000 May;19(5 Suppl):S66-71. doi: 10.1097/00006454-200005001-00010. Pediatr Infect Dis J. 2000. PMID: 10821474 Clinical Trial. No abstract available.
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M. Belshe RB, et al. N Engl J Med. 1998 May 14;338(20):1405-12. doi: 10.1056/NEJM199805143382002. N Engl J Med. 1998. PMID: 9580647 Clinical Trial.
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. Mascola JR, et al. Among authors: belshe rb. J Infect Dis. 1996 Feb;173(2):340-8. doi: 10.1093/infdis/173.2.340. J Infect Dis. 1996. PMID: 8568294 Clinical Trial.
Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, Dolin R, Matthews T, Weinhold K, Bolognesi DP, Sposto R, et al. Belshe RB, et al. JAMA. 1994 Aug 10;272(6):475-80. doi: 10.1001/jama.272.6.475. JAMA. 1994. PMID: 7913731 Clinical Trial.
HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
Gorse GJ, Patel GB, Belshe RB; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Gorse GJ, et al. Among authors: belshe rb. AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1175-89. doi: 10.1089/088922201316912781. AIDS Res Hum Retroviruses. 2001. PMID: 11522187 Clinical Trial.
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB, Gorse GJ, Mulligan MJ, Evans TG, Keefer MC, Excler JL, Duliege AM, Tartaglia J, Cox WI, McNamara J, Hwang KL, Bradney A, Montefiori D, Weinhold KJ. Belshe RB, et al. AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009. AIDS. 1998. PMID: 9875578 Clinical Trial.
240 results
Jump to page
Feedback